Calmangafodipir - Pledpharma

Drug Profile

Calmangafodipir - Pledpharma

Alternative Names: Aladote; PledOx; PP 100 01A; PP-095; PP-100-01

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PledPharma
  • Developer PledPharma; Solasia Pharma
  • Class Acetates; Chemoprotectants; Ethylenediamines; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chemotherapy-induced damage
  • Phase I Liver failure

Most Recent Events

  • 01 Dec 2017 Phase-I clinical trials in Chemotherapy induced damage (Prevention, In volunteers) in Japan (IV)
  • 20 Nov 2017 PledPharma and Solasia Pharma agree to co-promote and co-develop calmangafodipir in Japan, China, Hong Kong, Macau, South Korea and Taiwan for Chemotherapy induced damage (Prevention)
  • 20 Nov 2017 PledPharma and Solasia plan a phase I trial for Chemotherapy induced damage (Prevention) in Japanese and Caucasian healthy volunteers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top